Symbols / XTNT $0.52 -1.55% Xtant Medical Holdings, Inc.

Healthcare • Medical Devices • United States • ASE
XTNT Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Sean E. Browne
Exch · Country ASE · United States
Market Cap 72.14M
Enterprise Value 84.93M
Income 4.97M
Sales 133.93M
FCF (ttm) 6.50M
Book/sh 0.36
Cash/sh 0.12
Employees 151
Insider 10d —
IPO Jul 01, 2010
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 17.17
Forward P/E -25.75
PEG 1.74
P/S 0.54
P/B 1.41
P/C —
EV/EBITDA 6.79
EV/Sales 0.63
Quick Ratio 1.18
Current Ratio 2.65
Debt/Eq 56.36
LT Debt/Eq —
EPS (ttm) 0.03
EPS next Y -0.02
EPS Growth —
Revenue Growth 2.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-31
ROA 4.84%
ROE 10.59%
ROIC —
Gross Margin 62.92%
Oper. Margin -2.92%
Profit Margin 3.71%
Shs Outstand 140.07M
Shs Float 54.10M
Insider Own 13.86%
Instit Own 57.94%
Short Float 0.02%
Short Ratio 0.07
Short Interest 12.78K
52W High 0.95
vs 52W High -45.79%
52W Low 0.44
vs 52W Low 17.05%
Beta -0.12
Impl. Vol. —
Rel Volume 1.43
Avg Volume 139.35K
Volume 199.02K
Target (mean) $1.10
Tgt Median $1.10
Tgt Low $1.00
Tgt High $1.20
# Analysts 2
Recom None
Prev Close $0.52
Price $0.52
Change -1.55%
About

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor Pro, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers cervical products comprising Spider cervical plating, Streamline OCT system, and CervAlign systems; thoracolumbar products, such as of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; Silex sacroiliac joint fusion systems; interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; Contact ALP (Anterior Lumbar Plate) System; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. The company is headquartered in Belgrade, Montana.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$1.10
Mean price target
2. Current target
$0.50
Latest analyst target
3. DCF / Fair value
$0.83
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.50
Low
$1.00
High
$1.20
Mean
$1.10

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-31 main BTIG Buy → Buy $1
2025-11-11 main BTIG Buy → Buy $2
2024-05-16 main BTIG Buy → Buy $3
2023-12-05 init BTIG — → Buy $2
2023-07-11 main Craig-Hallum Buy → Buy $1
2023-04-26 init Craig-Hallum — → Buy $1
2019-05-17 down Maxim Group Buy → Hold —
2016-12-08 init Maxim Group — → Buy $2
2016-11-30 init Aegis Capital — → Buy $4
News
RSS: Latest XTNT news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-14 BAKEWELL JOHN K Director — 158,228 $0.00 $0
2025-11-14 BAKEWELL JOHN K Director — 158,228 $0.00 $0
2025-11-14 LIPSCHULTZ TYLER P Director — 158,228 $0.00 $0
2025-11-14 VIZIRGIANAKIS STAVROS G Director — 553,797 $0.00 $0
2025-11-14 BROWNE SEAN E. Chief Executive Officer — 394,937 $0.00 $0
2025-11-14 NEILS SCOTT C Chief Financial Officer — 263,291 $0.00 $0
2025-11-14 SCHALLENBERGER MARK A. Chief Operating Officer — 292,253 $0.00 $0
2025-11-14 BEESON JONN R. Director — 158,228 $0.00 $0
2025-11-14 JAIN ABHINAV Director — 158,228 $0.00 $0
2025-04-10 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 73,114,592 $0.42 $30,708,129
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
133.93
+14.21%
117.27
+28.44%
91.30
+57.50%
57.97
Operating Revenue
133.93
+14.21%
117.27
+28.44%
91.30
+57.50%
57.97
Cost Of Revenue
49.65
+1.23%
49.05
+36.88%
35.84
+38.73%
25.83
Reconciled Cost Of Revenue
49.65
+1.23%
49.05
+36.88%
35.84
+38.73%
25.83
Gross Profit
84.27
+23.54%
68.22
+22.98%
55.47
+72.60%
32.14
Operating Expense
76.99
-4.11%
80.29
+22.35%
65.62
+68.74%
38.89
Research And Development
2.10
-11.87%
2.38
+78.52%
1.34
+46.01%
0.92
Selling General And Administration
74.89
-3.87%
77.91
+21.18%
64.29
+69.28%
37.98
Selling And Marketing Expense
45.51
-7.52%
49.21
+28.03%
38.44
+70.73%
22.52
General And Administrative Expense
29.38
+2.38%
28.69
+10.99%
25.85
+67.18%
15.46
Other Gand A
29.38
+2.38%
28.69
+10.99%
25.85
+67.18%
15.46
Total Expenses
126.64
-2.09%
129.34
+27.48%
101.46
+56.76%
64.72
Operating Income
7.28
+160.33%
-12.07
-18.86%
-10.16
-50.38%
-6.75
Total Operating Income As Reported
7.28
+160.33%
-12.07
-18.86%
-10.16
-50.38%
-6.75
EBITDA
15.89
+301.76%
-7.88
-255.23%
5.08
+193.43%
-5.43
Normalized EBITDA
12.67
+260.78%
-7.88
-14.51%
-6.88
-26.73%
-5.43
Reconciled Depreciation
5.22
+23.65%
4.22
+33.08%
3.17
+145.67%
1.29
EBIT
10.67
+188.18%
-12.10
-736.61%
1.90
+128.27%
-6.72
Total Unusual Items
3.22
+64320.00%
0.01
-99.96%
11.96
0.00
Total Unusual Items Excluding Goodwill
3.22
+64320.00%
0.01
-99.96%
11.96
0.00
Special Income Charges
3.28
0.00
-100.00%
11.69
0.00
Restructuring And Mergern Acquisition
—
0.00
+100.00%
-11.69
0.00
Net Income
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Pretax Income
7.00
+143.05%
-16.26
-1468.18%
-1.04
+87.68%
-8.42
Net Non Operating Interest Income Expense
-3.58
+14.01%
-4.16
-49.16%
-2.79
-67.91%
-1.66
Interest Expense Non Operating
3.67
-11.75%
4.16
+41.59%
2.94
+73.64%
1.69
Net Interest Income
-3.58
+14.01%
-4.16
-49.16%
-2.79
-67.91%
-1.66
Interest Expense
3.67
-11.75%
4.16
+41.59%
2.94
+73.64%
1.69
Interest Income Non Operating
0.09
0.00
-100.00%
0.15
+380.65%
0.03
Interest Income
0.09
0.00
-100.00%
0.15
+380.65%
0.03
Other Income Expense
3.29
+11864.29%
-0.03
-100.24%
11.91
—
Other Non Operating Income Expenses
0.07
+321.21%
-0.03
+32.65%
-0.05
—
Gain On Sale Of Security
-0.06
-1300.00%
0.01
-98.11%
0.27
—
Gain On Sale Of Business
3.28
0.00
—
—
Tax Provision
2.03
+984.49%
0.19
+111.02%
-1.70
-2559.42%
0.07
Tax Rate For Calcs
0.00
+38.10%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.93
+88860.95%
0.00
-99.96%
2.51
0.00
Net Income Including Noncontrolling Interests
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Net Income From Continuing Operation Net Minority Interest
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Net Income From Continuing And Discontinued Operation
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Net Income Continuous Operations
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Normalized Income
2.69
+116.33%
-16.45
-87.23%
-8.79
-3.57%
-8.48
Net Income Common Stockholders
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Diluted EPS
0.03
+125.00%
-0.12
-1300.00%
0.01
+111.11%
-0.09
Basic EPS
0.04
+133.33%
-0.12
-1300.00%
0.01
+111.11%
-0.09
Basic Average Shares
139.53
+4.39%
133.67
+12.24%
119.09
+26.58%
94.09
Diluted Average Shares
150.04
+12.25%
133.67
+5.42%
126.79
+34.76%
94.09
Diluted NI Availto Com Stockholders
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
94.14
+0.33%
93.84
+1.32%
92.61
+53.77%
60.23
Current Assets
78.25
+16.58%
67.12
+3.46%
64.87
+31.53%
49.32
Cash Cash Equivalents And Short Term Investments
17.05
+175.09%
6.20
+8.47%
5.71
-71.84%
20.30
Cash And Cash Equivalents
17.05
+175.09%
6.20
+8.47%
5.71
-71.84%
20.30
Receivables
28.27
+36.81%
20.66
-0.34%
20.73
+91.02%
10.85
Accounts Receivable
17.80
-13.83%
20.66
-0.34%
20.73
+91.02%
10.85
Gross Accounts Receivable
19.97
-9.63%
22.10
+2.06%
21.65
+90.46%
11.37
Allowance For Doubtful Accounts Receivable
-2.17
-50.66%
-1.44
-56.20%
-0.92
-78.64%
-0.52
Inventory
30.26
-21.67%
38.63
+4.74%
36.88
+113.39%
17.29
Raw Materials
5.69
-14.09%
6.62
-8.90%
7.27
+29.16%
5.63
Work In Process
4.80
+70.66%
2.81
+80.03%
1.56
+95.74%
0.80
Finished Goods
19.77
-32.28%
29.20
+4.08%
28.05
+158.35%
10.86
Prepaid Assets
—
—
—
—
Restricted Cash
0.28
+1150.00%
0.02
-89.42%
0.21
-0.48%
0.21
Other Current Assets
2.39
+49.22%
1.60
+20.38%
1.33
+97.62%
0.67
Total Non Current Assets
15.90
-40.50%
26.72
-3.68%
27.74
+154.27%
10.91
Net PPE
9.39
-14.29%
10.96
+7.29%
10.21
+42.57%
7.17
Gross PPE
31.60
+2.61%
30.80
+3.02%
29.89
+18.97%
25.13
Accumulated Depreciation
-22.21
-11.95%
-19.84
-0.80%
-19.68
-9.55%
-17.96
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
1.61
-0.12%
1.61
+3.53%
1.56
+22.55%
1.27
Other Properties
25.50
+2.74%
24.83
+3.49%
23.99
+21.45%
19.75
Leases
4.48
+2.92%
4.36
+0.21%
4.35
+5.90%
4.11
Goodwill And Other Intangible Assets
6.37
-59.30%
15.66
-9.94%
17.39
+389.91%
3.55
Goodwill
6.07
-16.82%
7.30
+0.00%
7.30
+127.83%
3.21
Other Intangible Assets
0.30
-96.42%
8.36
-17.14%
10.09
+2831.69%
0.34
Other Non Current Assets
0.13
+29.13%
0.10
-26.95%
0.14
-28.43%
0.20
Total Liabilities Net Minority Interest
43.19
-15.10%
50.87
+23.29%
41.26
+58.35%
26.06
Current Liabilities
29.48
+3.16%
28.58
+24.32%
22.99
+51.07%
15.22
Payables And Accrued Expenses
14.47
-7.77%
15.69
-10.21%
17.47
+94.45%
8.99
Payables
12.75
-8.16%
13.89
-12.91%
15.94
+100.45%
7.95
Accounts Payable
3.84
-51.45%
7.92
+12.25%
7.05
+102.12%
3.49
Other Payable
6.73
+20.86%
5.57
-37.40%
8.89
+99.15%
4.46
Current Accrued Expenses
1.72
-4.77%
1.80
+17.92%
1.53
+48.16%
1.03
Total Tax Payable
2.18
+441.69%
0.40
—
—
Current Debt And Capital Lease Obligation
15.01
+16.46%
12.89
+133.68%
5.52
-11.47%
6.23
Current Debt
14.36
+18.46%
12.12
+162.22%
4.62
-19.08%
5.71
Other Current Borrowings
3.50
—
—
2.33
Current Capital Lease Obligation
0.66
-14.90%
0.77
-13.74%
0.90
+72.12%
0.52
Total Non Current Liabilities Net Minority Interest
13.71
-38.51%
22.29
+22.00%
18.27
+68.57%
10.84
Long Term Debt And Capital Lease Obligation
13.70
-38.42%
22.25
+23.33%
18.04
+66.44%
10.84
Long Term Debt
11.03
-49.97%
22.04
+28.37%
17.17
+77.22%
9.69
Long Term Capital Lease Obligation
2.68
+1156.81%
0.21
-75.66%
0.88
-24.11%
1.15
Non Current Deferred Liabilities
0.01
-88.10%
0.04
+100.00%
0.02
0.00
Non Current Deferred Taxes Liabilities
0.01
-88.10%
0.04
+100.00%
0.02
0.00
Stockholders Equity
50.95
+18.60%
42.96
-16.33%
51.35
+50.27%
34.17
Common Stock Equity
50.95
+18.60%
42.96
-16.33%
51.35
+50.27%
34.17
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
140.04
+0.71%
139.05
+6.81%
130.18
+19.57%
108.87
Ordinary Shares Number
140.04
+0.71%
139.05
+6.81%
130.18
+19.57%
108.87
Additional Paid In Capital
305.44
+0.89%
302.74
+2.86%
294.33
+5.93%
277.84
Retained Earnings
-254.49
+1.92%
-259.46
-6.77%
-243.01
+0.27%
-243.67
Gains Losses Not Affecting Retained Earnings
0.00
+100.00%
-0.32
-1189.66%
0.03
0.00
Other Equity Adjustments
—
-0.32
-1189.66%
0.03
—
Total Equity Gross Minority Interest
50.95
+18.60%
42.96
-16.33%
51.35
+50.27%
34.17
Total Capitalization
61.98
-4.65%
65.00
-5.13%
68.52
+56.22%
43.86
Working Capital
48.76
+26.54%
38.53
-7.98%
41.88
+22.81%
34.10
Invested Capital
76.34
-1.02%
77.12
+5.45%
73.14
+47.54%
49.57
Total Debt
28.72
-18.29%
35.14
+49.17%
23.56
+38.00%
17.07
Net Debt
8.33
-70.21%
27.96
+73.94%
16.07
—
Capital Lease Obligations
3.33
+238.48%
0.98
-44.35%
1.77
+5.80%
1.67
Net Tangible Assets
44.58
+63.27%
27.30
-19.60%
33.96
+10.91%
30.62
Tangible Book Value
44.58
+63.27%
27.30
-19.60%
33.96
+10.91%
30.62
Line Of Credit
10.86
-10.42%
12.12
+162.22%
4.62
+36.79%
3.38
Non Current Accrued Expenses
—
0.00
-100.00%
0.21
0.00
Notes Receivable
10.46
0.00
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
12.55
+205.46%
-11.90
-25.02%
-9.52
-78.15%
-5.34
Cash Flow From Continuing Operating Activities
12.55
+205.46%
-11.90
-25.02%
-9.52
-78.15%
-5.34
Net Income From Continuing Operations
4.97
+130.23%
-16.45
-2592.27%
0.66
+107.78%
-8.48
Depreciation Amortization Depletion
5.22
+23.65%
4.22
+33.08%
3.17
+145.67%
1.29
Depreciation And Amortization
5.22
+23.65%
4.22
+33.08%
3.17
+145.67%
1.29
Other Non Cash Items
0.46
-10.83%
0.52
+104.58%
-11.29
-4864.56%
0.24
Stock Based Compensation
2.89
-29.75%
4.12
+50.31%
2.74
+11.16%
2.46
Provisionand Write Offof Assets
5.07
+287.84%
1.31
+53.16%
0.85
-58.44%
2.06
Deferred Tax
—
0.02
+101.10%
-1.90
0.00
Deferred Income Tax
—
0.02
+101.10%
-1.90
0.00
Operating Gains Losses
-3.03
-1047.73%
-0.26
-129.57%
-0.12
-23.66%
-0.09
Gain Loss On Sale Of PPE
0.25
+195.08%
-0.26
-129.57%
-0.12
-23.66%
-0.09
Change In Working Capital
-3.05
+43.05%
-5.35
-47.19%
-3.63
-29.28%
-2.81
Change In Receivables
-0.59
+21.72%
-0.76
+91.36%
-8.74
-121.67%
-3.94
Changes In Account Receivables
-0.59
+21.72%
-0.76
+91.36%
-8.74
-121.67%
-3.94
Change In Inventory
-2.00
+19.85%
-2.49
-32.24%
-1.89
-63.72%
-1.15
Change In Prepaid Assets
-1.54
-605.05%
-0.22
-199.09%
0.22
-15.71%
0.26
Change In Payables And Accrued Expense
1.08
+157.44%
-1.88
-127.81%
6.77
+234.88%
2.02
Change In Accrued Expense
4.20
+244.01%
-2.92
-176.95%
3.79
+230.54%
1.15
Change In Payable
-3.12
-401.74%
1.03
-65.34%
2.98
+240.57%
0.88
Change In Account Payable
-3.12
-401.74%
1.03
-65.34%
2.98
+240.57%
0.88
Investing Cash Flow
7.90
+311.77%
-3.73
+84.95%
-24.78
-1489.74%
-1.56
Cash Flow From Continuing Investing Activities
7.90
+311.77%
-3.73
+84.95%
-24.78
-1489.74%
-1.56
Net PPE Purchase And Sale
-2.15
+42.36%
-3.73
-191.18%
-1.28
+17.83%
-1.56
Purchase Of PPE
-2.38
+42.09%
-4.11
-182.49%
-1.46
+17.46%
-1.76
Sale Of PPE
0.23
-39.43%
0.38
+118.86%
0.17
-14.63%
0.20
Capital Expenditure
-2.38
+42.09%
-4.11
-182.49%
-1.46
+17.46%
-1.76
Net Business Purchase And Sale
10.05
0.00
+100.00%
-23.50
0.00
Purchase Of Business
—
0.00
+100.00%
-23.50
0.00
Gain Loss On Sale Of Business
-3.28
0.00
—
—
Financing Cash Flow
-9.57
-159.54%
16.07
-18.37%
19.69
+118.30%
9.02
Cash Flow From Continuing Financing Activities
-9.57
-159.54%
16.07
-18.37%
19.69
+118.30%
9.02
Net Issuance Payments Of Debt
-9.33
-175.04%
12.43
+101.18%
6.18
+2223.71%
-0.29
Issuance Of Debt
100.07
-14.94%
117.64
+41.36%
83.22
+53.46%
54.23
Repayment Of Debt
-109.40
-3.98%
-105.21
-36.56%
-77.04
-41.30%
-54.52
Long Term Debt Issuance
0.00
-100.00%
5.00
+0.00%
5.00
0.00
Long Term Debt Payments
-8.07
-12310.77%
-0.07
-3.17%
-0.06
-26.00%
-0.05
Net Long Term Debt Issuance
-8.07
-263.47%
4.93
-0.04%
4.94
+9974.00%
-0.05
Short Term Debt Issuance
100.07
-11.16%
112.64
+44.01%
78.22
+44.24%
54.23
Short Term Debt Payments
-101.33
+3.63%
-105.14
-36.59%
-76.98
-41.32%
-54.47
Net Short Term Debt Issuance
-1.26
-116.84%
7.50
+503.22%
1.24
+615.77%
-0.24
Net Common Stock Issuance
-0.07
-101.46%
4.46
-68.20%
14.01
+50.48%
9.31
Common Stock Payments
-0.07
—
—
—
Repurchase Of Capital Stock
-0.07
—
—
—
Proceeds From Stock Option Exercised
0.00
-100.00%
0.01
0.00
—
Net Other Financing Charges
-0.17
+78.89%
-0.83
-65.80%
-0.50
—
Changes In Cash
10.88
+2332.89%
0.45
+103.06%
-14.61
-789.06%
2.12
Effect Of Exchange Rate Changes
0.23
+255.70%
-0.15
-720.83%
0.02
0.00
Beginning Cash Position
6.22
+5.03%
5.92
-71.12%
20.51
+11.53%
18.39
End Cash Position
17.33
+178.54%
6.22
+5.03%
5.92
-71.12%
20.51
Free Cash Flow
10.16
+163.49%
-16.01
-45.92%
-10.97
-54.41%
-7.11
Interest Paid Supplemental Data
—
3.64
+42.55%
2.55
+75.52%
1.45
Common Stock Issuance
—
4.46
-68.20%
14.01
+50.48%
9.31
Issuance Of Capital Stock
—
4.46
-68.20%
14.01
+50.48%
9.31
Sale Of Business
10.05
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category